Comparing veterinary medicines by active substance: analogue, generic and substitute

A shelf holds two boxes. The names on the front are different, the prices are different, and the composition line on both reads the same substance. The question that follows is entirely reasonable: are these the same medicine?

The answer is that the composition line has settled one of seven questions. This page sets out the other six, explains why a shared molecule can still behave differently, and describes what a generic authorisation actually certifies — which is more than people assume in one respect and less in another.

What an active substance and an INN are

The active substance is the component of a medicine responsible for its pharmacological effect. Everything else in the formulation — solvents, preservatives, adjuvants, binders, flavourings — is an excipient, present to make the active substance deliverable, stable and acceptable to the animal.

The INN, or international nonproprietary name, is the globally agreed generic name for that substance. The system is maintained by the World Health Organization so that a molecule is called the same thing in every country and by every manufacturer, which is what makes cross-brand comparison possible at all. A few substances used only in animals carry names established through veterinary channels rather than the INN list, but the principle is identical.

What an INN does not carry is everything else. It says nothing about how much is present, what form the product takes, how it is administered, which animals it was tested in, or how long produce must be withheld afterwards. Reading a shared INN as evidence of equivalence is reading a surname as evidence of a shared address.

Analogue, generic and substitute are three different claims

These words are used interchangeably in conversation and mean quite different things on paper.

Bioequivalence is the technical core of the middle row and is worth stating plainly. A generic applicant does not repeat the original clinical development. Instead it demonstrates that its product delivers the same active substance to the body at a comparable rate and extent as the reference product — in the target species, by the intended route — against criteria harmonised internationally through VICH. The reasoning is that if the concentration profile in the animal is equivalent, the clinical effect will be too.

That is a strong claim about a narrow thing. It holds between the generic and the reference product named in its authorisation, for the strength and form assessed. It is not a general statement that all products containing the substance are mutually swappable.

The seven properties that have to agree

Each rung fails in its own characteristic way.

Strength. Two products at different concentrations require different volumes to deliver the same amount, and the arithmetic is where errors enter. This is the practical reason reading the units correctly is a prerequisite to any comparison at all.

Pharmaceutical form and route. A form is not a packaging choice; it determines where the substance is released and how fast. An oral premix and an injectable solution containing the same substance have different absorption, different onset and different applicability.

Target species. A product is authorised for named species, and a species absent from that list was not assessed. Using it there is off-label use, which most jurisdictions permit under defined conditions and only through a veterinarian.

Indication. The authorised use describes what the product was shown to do. A substance active against a group of organisms in general is not thereby authorised against every condition those organisms cause.

Withdrawal periods. In food-producing animals this rung can differ sharply between two products that match on all the others, because the period depends on the formulation. Substituting on the assumption that the waiting time travels with the substance is one of the more expensive mistakes available — see withdrawal periods.

Why the salt or ester changes the answer

Rung 1 says “including its salt or ester form”, and that qualifier does a great deal of work.

An active substance is frequently formulated not as the bare molecule but as a salt or an ester of it. The pharmacologically active part is unchanged; what changes is solubility. A poorly soluble form injected into muscle dissolves slowly, producing a low but sustained concentration over days. A highly soluble form dissolves at once, producing a high early concentration that falls away quickly.

That difference is the entire basis of long-acting preparations, and it is invisible if the comparison stops at the base name. Two injectables can share a substance and differ in how often they are given, how long they act, how long residues persist and therefore what the withdrawal period is. The composition line on the label states the exact form for this reason, and it is the part of the line worth reading rather than skimming.

Comparing two products in practice

The comparison is mechanical, and doing it on paper takes a few minutes.

1. Put the approved labelling for both products side by side — the package leaflet or summary of product characteristics, not the carton.
2. Read the composition line on each, including the salt or ester, and the strength with its unit.
3. Compare pharmaceutical form and route.
4. Compare the list of target species, and check the animal in question is on both lists.
5. Compare the authorised indications.
6. For food-producing animals, compare every withdrawal period — meat, milk, eggs — separately.
7. Note the differences that remain, and take them to the veterinarian responsible for the animal. That is the point at which a comparison becomes a decision.

The last step is not a formality. Substitution in a prescription context is a clinical and legal act, and the person who signs for it carries the consequence, including for any residue in food. What the keeper contributes is the accurate side-by-side, which is often the part nobody has done.

Where public information helps and where it stops

Most regulators publish a searchable register of authorised veterinary medicines — the European Medicines Agency and national agencies in the EU, the Veterinary Medicines Directorate in the United Kingdom, Animal Drugs @ FDA in the United States — and these are the right places to establish what exists, what it contains and what it was authorised for.

What they cannot tell you is whether a substitution is appropriate for a particular animal on a particular day. A register is a record of authorisations; it holds no information about the animal in front of you, its history, or what else it has received. The register settles rungs 1 to 7. The animal settles the rest.

Bottom line

An active substance identified by its INN is a starting point for comparing two veterinary medicines and nothing more. A generic carries a real and specific claim — bioequivalence to a named reference product, demonstrated in the target species — while an analogue carries none. Before two products can be treated as interchangeable, seven properties must agree: substance including its salt or ester, strength, pharmaceutical form, route, target species, authorised indication, and the withdrawal periods for food-producing animals. The salt or ester alone can turn one product into a long-acting version of another, with different dosing intervals and a different waiting time before produce may be sold. Do the side-by-side comparison from the approved labelling, then hand the differences to the veterinarian who is accountable for the substitution.